AHK-Cu is a copper tripeptide complex structurally related to GHK-Cu, utilized primarily for hair follicle stimulation and tissue repair. Users typically run a daily dose of 2 mg, though reported protocols range widely from 250 µg to 50 mg. While injection-site reactions occasionally surface, other common side effects like flushing or GI distress have not been reported. The evidence base for this peptide remains thin, as all human use is off-label and current research lacks published clinical results to support its exploratory indications.
Data last updated
Measured on 3 of 6 axes
Evidence shape
AHK-Cu currently lacks human clinical evidence, as no published trials exist to support its use in any therapeutic indication. Research remains restricted to preclinical and mechanistic studies, meaning there is no data from human subjects to establish safety or efficacy. Because the peptide has not progressed into registered human trials, the current evidence base is entirely theoretical. This absence of clinical data indicates that any potential application remains speculative and unverified by the standard rigor of human research.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How AHK-CU is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
About half of community users inject AHK‑CU subcutaneously once daily, typically 1–2 mg (range 250 µg–50 mg); a similar number reported an unspecified schedule with comparable doses, and no cycling regimen was mentioned.